Cytokinetics, Incorporated · NASDAQ:CYTK
Callos Andrew sold 15,857 Cytokinetics, Incorporated shares (Form 4)
Traded May 1, 2026 · Filed May 4, 2026
On May 1, 2026, Callos Andrew (EVP, Chief Commercial Officer) sold 15,857 Cytokinetics, Incorporated shares at US$65.00 for US$1.03M under a trading plan, leaving 58,555 shares. Filed May 4, 2026 (Form 4).
- Sold
- 15,857 shares
- Price
- US$65.00
- Value
- US$1.03M
- Holding after
- 58,555 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- EVP, Chief Commercial Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| May 1, 2026 | Common Stock | Option exercise | 15,857 | US$37.63 | 74,412 | Direct |
| May 1, 2026 | Common Stock | Sale | 15,857 | US$65.00 | 58,555 | Direct |
Source
Related
- Cytokinetics, Incorporated
- Callos Andrew
- Cytokinetics, Incorporated shareholders
- Form 4 · Callos Andrew · Aug 31, 2026
- Form 4 · Callos Andrew · Jul 30, 2026
- Form 4 · Callos Andrew · Jul 2, 2026
- Form 4 · Callos Andrew · Jun 1, 2026
- Form 4 · Callos Andrew · May 5, 2026
- Form 4 · Malik Fady Ibraham · Oct 20, 2026
- Form 4 · Daly James M · Oct 20, 2026
- Form 4 · Henderson John T · Oct 20, 2026
- Form 4 · Wysenski Nancy · Oct 20, 2026
- Form 4 · Harrington Robert Arthur · Oct 20, 2026